SCHEMBL10272402

SCHEMBL10272402

Cc1cccc(N2CCOCC2=O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48
MAPK1 P28482 1/20 0.48
PTGS2 P35354 1/20 0.46
HSD11B1 P28845 3/20 0.46
PIK3CD O00329 3/20 0.46
DRD2 P14416 1/20 0.46
DRD3 P35462 1/20 0.46
PIK3CA P42336 2/20 0.46
PIK3CG P48736 2/20 0.46
PIK3CB P42338 1/20 0.46
MAP4K1 Q92918 2/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
ALOX5 P09917 1/20 0.44
F10 P00742 1/20 0.44
HSP90AA1 P07900 1/20 0.44
MGLL Q99685 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29740650 0.83 PIK3CD (0.49) ALDH1A1MAPTPTGS2PIK3CDPIK3CA
SCHEMBL20124865 0.83 PIK3CD (0.49) ALDH1A1MAPTPTGS2PIK3CDPIK3CA
SCHEMBL2940366 0.81 MAP4K1 (0.50) ALDH1A1L3MBTL1MAPTPTGS2PIK3CD
SCHEMBL1438679 0.81 PIK3CD (0.46) PTGS2PIK3CDDRD2DRD3PIK3CA
SCHEMBL20502398 0.81 ALDH1A1 (0.48) ALDH1A1L3MBTL1PTGS2HSD11B1PIK3CD
SCHEMBL13097259 0.81 F10 (0.49) PTGS2PIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL7895104 0.81 MAP4K1 (0.53) PTGS2PIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL10224185 0.81 PIK3CD (0.43) PTGS2PIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL10224168 0.81 DRD2 (0.47) PTGS2PIK3CDDRD2DRD3PIK3CA
SCHEMBL92872 0.80 PTGS2 (0.64) PTGS2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107603-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2022174253-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-08-18 WO disclosed
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 EP disclosed
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 EP disclosed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 US disclosed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 US disclosed
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ANTABIO SAS (FR) 2016-09-22 US disclosed
EP-2373634-B1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARM CO LTD (JP) 2015-11-11 EP disclosed
US-8987242-B2 Morpholinone compounds as factor IXA inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-8980916-B2 Factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-17 US disclosed
US-20140322195-A1 Factor IXA Inhibitors MERCK SHARP & DOHME LLC 2014-10-30 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-06-09 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT ALDH1A1 947/4885L3MBTL1 4883/4885MAPT 2847/4885
US-20140322195-A1 Factor IXA Inhibitors F9, F12, F11 ALDH1A1 1489/4885L3MBTL1 4779/4885MAPT 3872/4885
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 ALDH1A1 2444/4885L3MBTL1 3657/4885MAPT 3534/4885
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS PIK3R3, JAK2, JAK3 ALDH1A1 3131/4885L3MBTL1 3926/4885MAPT 4565/4885
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ME1, TALDO1, COASY ALDH1A1 40/4885L3MBTL1 383/4885MAPT 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.